SYN-1147-M0011 mgCHF 270.00
SYN-1147-M0055 mgCHF 454.00
SYN-1147-M01010 mgCHF 653.00
|Solubility||Soluble in DMSO.|
|Declaration||Manufactured by SynKinase.|
|Other Product Data||
Target: PDGFR | Kinase Group: RTK | Substrate: Tyrosine
Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
Bentamapimod (AS602801) is a novel and orally active c-Jun-N-Terminal Kinase Inhibitor highly specific for JNK kinases. The inhibitor Bentamapimod (AS602801) is a potent anti-inflammatory agent which has been shown to reduce the disease burden in several pre-clinical models for endometriosis, and has the potential to be effective in addressing the causes of post-operative abdominal adhesions. Pre-clinical data have demonstrated Bentamapimod to be an effective anti-inflammatory compound with anti-fibrotic properties. Bentamapimod (AS602801) showed good bioavailability in rats (F=50%). It does cross the blood brain barrier, with 98% brain penetration the drug has been well tolerated so far. Bentamapimod (AS602801) is a potent and selective JNK inhibitor with therapeutic potential in MS and fibrosis as well.
- Kinase targets and inhibitors for the treatment of airway inflammatory diseases: the next generation of drugs for severe asthma and COPD? I.M. Adcock & G. Caramori; BioDrugs 18, 167 (2004)